Treats infections caused by susceptible strains of the designated organisms in the…. ANDA 216761, held by Gland. Erythromycin Lactobionate.
As of Nov 16, 2026, ANDA 216761 (Erythromycin Lactobionate), held by Gland, was first approved by FDA on Nov 19, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 19, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Erythromycin LactobionateEQ 500MG BASE/VIAL · injectable;injection | Erythromycin Lactobionate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters